schliessen

Filtern

 

Bibliotheken

Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?

The expanding armamentarium of agents for the therapy of advanced clear cell renal cell carcinoma (RCC) warrants further investigation of optimal patient selection. To analyze the second and subsequent line of targeted therapies for advanced RCC while integrating clinical and molecular markers and i... Full description

Journal Title: European Urology 2012, Vol.61(2), pp.307-316
Main Author: Sonpavde, Guru
Other Authors: Choueiri, Toni K , Escudier, Bernard , Ficarra, Vincenzo , Hutson, Thomas E , Mulders, Peter F , Patard, Jean-Jacques , Rini, Brian I , Staehler, Michael , Sternberg, Cora N , Stief, Christian G
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0302-2838 ; E-ISSN: 1873-7560 ; DOI: 10.1016/j.eururo.2011.10.032
Link: https://www.sciencedirect.com/science/article/pii/S0302283811011389
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_j_eururo_2011_10_032
title: Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?
format: Article
creator:
  • Sonpavde, Guru
  • Choueiri, Toni K
  • Escudier, Bernard
  • Ficarra, Vincenzo
  • Hutson, Thomas E
  • Mulders, Peter F
  • Patard, Jean-Jacques
  • Rini, Brian I
  • Staehler, Michael
  • Sternberg, Cora N
  • Stief, Christian G
subjects:
  • Renal Cell Carcinoma
  • Tyrosine Kinase Inhibitor
  • Second-Line Therapy
  • Axitinib
  • Everolimus
  • Medicine
ispartof: European Urology, 2012, Vol.61(2), pp.307-316
description: The expanding armamentarium of agents for the therapy of advanced clear cell renal cell carcinoma (RCC) warrants further investigation of optimal patient selection. To analyze the second and subsequent line of targeted therapies for advanced RCC while integrating clinical and molecular markers and imaging. Data were acquired from research published in peer-reviewed literature or presented at major conferences. Following first-line vascular endothelial growth factor (VEGF) inhibitors, second-line therapy with everolimus, a mammalian target of rapamycin inhibitor, and axitinib, a VEGF receptor tyrosine kinase inhibitor, have demonstrated benefits in progression-free survival (PFS). Sorafenib, pazopanib, and axitinib have demonstrated extension of PFS following cytokines. Optimal patient selection based on biomarkers is undergoing investigation. Clinical trials evaluating novel agents and combinations should be preferred....
language: eng
source:
identifier: ISSN: 0302-2838 ; E-ISSN: 1873-7560 ; DOI: 10.1016/j.eururo.2011.10.032
fulltext: fulltext
issn:
  • 0302-2838
  • 03022838
  • 1873-7560
  • 18737560
url: Link


@attributes
ID1651953858
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_j_eururo_2011_10_032
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_j_eururo_2011_10_032
sourcesystemPC
dbid
0--K
1--M
2.FO
3.~1
41B1
51P~
61~.
7457
84G.
97-5
108P~
11AABNK
12AAEDT
13AAKOC
14AAOAW
15AAQFI
16ABBQC
17ABFNM
18ABMZM
19ABYKQ
20ACDAQ
21ACRLP
22AEKER
23AEVXI
24AFKWA
25AFTJW
26AFXIZ
27AGHFR
28AGUBO
29AGYEJ
30AIKHN
31AITUG
32AJBFU
33AJOXV
34AJRQY
35AJUYK
36AMFUW
37ANZVX
38BLXMC
39BNPGV
40EO8
41EO9
42EP2
43EP3
44FDB
45FIRID
46FNPLU
47G-Q
48GBLVA
49J1W
50KOM
51LCYCR
52OAUVE
53OK.
54OW.
55P-8
56P-9
57PC.
58Q38
59RPZ
60SCC
61SDF
62SDG
63SEL
64SES
65SEW
66SSH
67SSZ
68T5K
69UV1
70Z5R
71~G-
pqid912428161
galeid275179692
display
typearticle
titleSequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?
creatorSonpavde, Guru ; Choueiri, Toni K ; Escudier, Bernard ; Ficarra, Vincenzo ; Hutson, Thomas E ; Mulders, Peter F ; Patard, Jean-Jacques ; Rini, Brian I ; Staehler, Michael ; Sternberg, Cora N ; Stief, Christian G
ispartofEuropean Urology, 2012, Vol.61(2), pp.307-316
identifier
subjectRenal Cell Carcinoma ; Tyrosine Kinase Inhibitor ; Second-Line Therapy ; Axitinib ; Everolimus ; Medicine
descriptionThe expanding armamentarium of agents for the therapy of advanced clear cell renal cell carcinoma (RCC) warrants further investigation of optimal patient selection. To analyze the second and subsequent line of targeted therapies for advanced RCC while integrating clinical and molecular markers and imaging. Data were acquired from research published in peer-reviewed literature or presented at major conferences. Following first-line vascular endothelial growth factor (VEGF) inhibitors, second-line therapy with everolimus, a mammalian target of rapamycin inhibitor, and axitinib, a VEGF receptor tyrosine kinase inhibitor, have demonstrated benefits in progression-free survival (PFS). Sorafenib, pazopanib, and axitinib have demonstrated extension of PFS following cytokines. Optimal patient selection based on biomarkers is undergoing investigation. Clinical trials evaluating novel agents and combinations should be preferred....
languageeng
source
version5
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/S0302283811011389$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Sonpavde, Guru
1Choueiri, Toni K
2Escudier, Bernard
3Ficarra, Vincenzo
4Hutson, Thomas E
5Mulders, Peter F
6Patard, Jean-Jacques
7Rini, Brian I
8Staehler, Michael
9Sternberg, Cora N
10Stief, Christian G
titleSequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?
description
subject
0Renal Cell Carcinoma
1Tyrosine Kinase Inhibitor
2Second-Line Therapy
3Axitinib
4Everolimus
5Medicine
general
0English
1Elsevier B.V
210.1016/j.eururo.2011.10.032
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_j_eururo_2011_10_032
issn
00302-2838
103022838
21873-7560
318737560
rsrctypearticle
creationdate2012
addtitleEuropean Urology
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1--M
2.FO
3.~1
41B1
51P~
61~.
7457
84G.
97-5
108P~
11AABNK
12AAEDT
13AAKOC
14AAOAW
15AAQFI
16ABBQC
17ABFNM
18ABMZM
19ABYKQ
20ACDAQ
21ACRLP
22AEKER
23AEVXI
24AFKWA
25AFTJW
26AFXIZ
27AGHFR
28AGUBO
29AGYEJ
30AIKHN
31AITUG
32AJBFU
33AJOXV
34AJRQY
35AJUYK
36AMFUW
37ANZVX
38BLXMC
39BNPGV
40EO8
41EO9
42EP2
43EP3
44FDB
45FIRID
46FNPLU
47G-Q
48GBLVA
49J1W
50KOM
51LCYCR
52OAUVE
53OK.
54OW.
55P-8
56P-9
57PC.
58Q38
59RPZ
60SCC
61SDF
62SDG
63SEL
64SES
65SEW
66SSH
67SSZ
68T5K
69UV1
70Z5R
71~G-
startdate20120101
enddate20121231
lsr40European Urology, 2012, Vol.61 (2), pp.307-316
doi10.1016/j.eururo.2011.10.032
citationpf 307 pt 316 vol 61 issue 2
lsr30VSR-Enriched:[galeid, pqid]
sort
titleSequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?
authorSonpavde, Guru ; Choueiri, Toni K ; Escudier, Bernard ; Ficarra, Vincenzo ; Hutson, Thomas E ; Mulders, Peter F ; Patard, Jean-Jacques ; Rini, Brian I ; Staehler, Michael ; Sternberg, Cora N ; Stief, Christian G
creationdate20120000
lso0120120000
facets
frbrgroupid8813450574233362470
frbrtype5
newrecords20190904
languageeng
topic
0Renal Cell Carcinoma
1Tyrosine Kinase Inhibitor
2Second-Line Therapy
3Axitinib
4Everolimus
5Medicine
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Sonpavde, Guru
1Choueiri, Toni K
2Escudier, Bernard
3Ficarra, Vincenzo
4Hutson, Thomas E
5Mulders, Peter F
6Patard, Jean-Jacques
7Rini, Brian I
8Staehler, Michael
9Sternberg, Cora N
10Stief, Christian G
jtitleEuropean Urology
creationdate2012
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Sonpavde
1Choueiri
2Escudier
3Ficarra
4Hutson
5Mulders
6Patard
7Rini
8Staehler
9Sternberg
10Stief
aufirst
0Guru
1Toni K
2Bernard
3Vincenzo
4Thomas E
5Peter F
6Jean-Jacques
7Brian I
8Michael
9Cora N
10Christian G
auinitG
auinit1G
au
0Sonpavde, Guru
1Choueiri, Toni K
2Escudier, Bernard
3Ficarra, Vincenzo
4Hutson, Thomas E
5Mulders, Peter F
6Patard, Jean-Jacques
7Rini, Brian I
8Staehler, Michael
9Sternberg, Cora N
10Stief, Christian G
atitleSequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?
jtitleEuropean Urology
date2012
risdate2012
volume61
issue2
spage307
epage316
pages307-316
issn0302-2838
eissn1873-7560
formatjournal
genrearticle
ristypeJOUR
abstract
pubElsevier B.V
doi10.1016/j.eururo.2011.10.032
lad01European Urology